EA201791624A1 - СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК - Google Patents

СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК

Info

Publication number
EA201791624A1
EA201791624A1 EA201791624A EA201791624A EA201791624A1 EA 201791624 A1 EA201791624 A1 EA 201791624A1 EA 201791624 A EA201791624 A EA 201791624A EA 201791624 A EA201791624 A EA 201791624A EA 201791624 A1 EA201791624 A1 EA 201791624A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
mrna
improve
splising
methods
Prior art date
Application number
EA201791624A
Other languages
English (en)
Other versions
EA037663B1 (ru
Inventor
Сьюзан А. Слогенхаупт
Грехэм Джонсон
Уилльям Д. Пакетт
Вэй Чжан
Хуан Маруган
Original Assignee
Те Дженерал Хоспитал Корпорейшн
Юнайтед Стейтс Дипартмент Оф Хелт Энд Хьюман Сервисиз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Дженерал Хоспитал Корпорейшн, Юнайтед Стейтс Дипартмент Оф Хелт Энд Хьюман Сервисиз filed Critical Те Дженерал Хоспитал Корпорейшн
Publication of EA201791624A1 publication Critical patent/EA201791624A1/ru
Publication of EA037663B1 publication Critical patent/EA037663B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Описаны соединения, которые могут применяться для улучшения сплайсинга мРНК в клетке. Иллюстративные описанные в настоящем тексте соединения могут применяться для улучшения сплайсинга мРНК в генах, содержащих по меньшей мере один экзон, заканчивающийся нуклеотидной последовательностью CAA. Описаны также способы получения указанных соединений и способы лечения заболеваний центральной нервной системы.
EA201791624A 2015-01-16 2016-01-15 СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК EA037663B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562104547P 2015-01-16 2015-01-16
US201562180380P 2015-06-16 2015-06-16
PCT/US2016/013553 WO2016115434A1 (en) 2015-01-16 2016-01-15 Compounds for improving mrna splicing

Publications (2)

Publication Number Publication Date
EA201791624A1 true EA201791624A1 (ru) 2018-06-29
EA037663B1 EA037663B1 (ru) 2021-04-28

Family

ID=56406434

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791624A EA037663B1 (ru) 2015-01-16 2016-01-15 СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК

Country Status (16)

Country Link
US (3) US10676475B2 (ru)
EP (2) EP3244891B9 (ru)
AU (2) AU2016206589B2 (ru)
BR (1) BR112017015019A2 (ru)
CA (2) CA2973949C (ru)
CL (2) CL2017001823A1 (ru)
DK (1) DK3244891T3 (ru)
EA (1) EA037663B1 (ru)
ES (1) ES2928714T3 (ru)
HU (1) HUE059891T2 (ru)
IL (2) IL253291B (ru)
MX (2) MX2017009295A (ru)
PL (1) PL3244891T3 (ru)
PT (1) PT3244891T (ru)
TW (2) TWI727939B (ru)
WO (1) WO2016115434A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009295A (es) * 2015-01-16 2018-03-07 Massachusetts Gen Hospital Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).
IL281633B (en) 2015-12-10 2022-07-01 Ptc Therapeutics Inc Methods for treating Huntington's disease
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
JP7129095B2 (ja) * 2017-02-20 2022-09-01 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
IL300875A (en) 2017-06-05 2023-04-01 Ptc Therapeutics Inc Compounds for the treatment of Huntington's disease
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019005980A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814357B1 (en) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020072504A1 (en) * 2018-10-01 2020-04-09 Genzyme Corporation Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
WO2020167628A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
US20220135568A1 (en) 2019-02-13 2022-05-05 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP2022522777A (ja) * 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
WO2020180770A1 (en) * 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US20210139517A1 (en) 2019-11-08 2021-05-13 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
JP2023506488A (ja) * 2019-12-12 2023-02-16 ピーティーシー セラピューティクス， インコーポレイテッド 家族性自律神経失調症を処置するための化合物
US20230047208A1 (en) 2020-01-02 2023-02-16 The General Hospital Corporation RNA Splicing Modulation
CN111777612B (zh) * 2020-06-05 2022-04-19 广东达元绿洲食品安全科技股份有限公司 一种6-苄基腺嘌呤半抗原、人工抗原及其在免疫检测中的应用
WO2022169864A1 (en) * 2021-02-05 2022-08-11 Ptc Therapeutics Inc. Methods for treating spinocerebellar ataxia type 3
CN113151296B (zh) * 2021-03-22 2022-09-13 云南中烟工业有限责任公司 一种烟草热激蛋白相关的基因及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3041340A (en) 1962-06-26 Method of preparing substituted
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB9613736D0 (en) 1996-07-01 1996-09-04 Hancock Tony Transport cradle for a skid-supported helicopter
SK12912000A3 (sk) 1998-02-26 2001-08-06 Aventis Pharmaceuticals Inc. 6,9-disubstituované 2-[trans-(4-aminocyklohexyl)amino]puríny, farmaceutické prostriedky obsahujúce tieto zlúčeniny a použitie
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
WO2005003290A2 (en) 2002-09-10 2005-01-13 The Regents Of The University Of California Methods and devices for determining a cell characteristic, and applications employing same
AU2004278773B2 (en) * 2003-10-03 2011-05-19 The General Hospital Corporation Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders
US20050153989A1 (en) * 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MY171289A (en) 2006-02-02 2019-10-07 Millennium Pharm Inc Inhibitors of e1 activating enzymes
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2681136C (en) 2007-03-23 2012-05-22 Amgen Inc. Heterocyclic compounds and their uses
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
AU2009299599A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic JAK kinase inhibitors
CA2748943A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011041655A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions
EA035030B1 (ru) * 2011-11-18 2020-04-20 Сарепта Терапьютикс, Инк. Модифицированные морфолиновые аналоги олигонуклеотидов
CZ306894B6 (cs) 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
CA2900779C (en) 2013-02-11 2021-10-26 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
US9938279B2 (en) 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
WO2015123365A1 (en) 2014-02-11 2015-08-20 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
MX2017009295A (es) * 2015-01-16 2018-03-07 Massachusetts Gen Hospital Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).

Also Published As

Publication number Publication date
CA2973949A1 (en) 2016-07-21
CL2017001823A1 (es) 2018-04-13
US20200283441A1 (en) 2020-09-10
IL253291A0 (en) 2017-09-28
AU2020277224B2 (en) 2022-12-22
US10676475B2 (en) 2020-06-09
ES2928714T9 (es) 2022-11-29
TWI727939B (zh) 2021-05-21
CL2019002167A1 (es) 2019-12-13
CA3199430A1 (en) 2016-07-21
WO2016115434A1 (en) 2016-07-21
TW202204345A (zh) 2022-02-01
EP3244891B1 (en) 2022-07-20
HUE059891T2 (hu) 2023-01-28
AU2016206589A1 (en) 2017-07-27
EP3244891A1 (en) 2017-11-22
EP3244891A4 (en) 2018-12-19
MX2022015737A (es) 2023-01-18
EP4115882A1 (en) 2023-01-11
CA2973949C (en) 2023-07-11
EA037663B1 (ru) 2021-04-28
IL253291B (en) 2021-10-31
PT3244891T (pt) 2022-10-20
AU2020277224A1 (en) 2020-12-24
MX2017009295A (es) 2018-03-07
US20180118748A1 (en) 2018-05-03
BR112017015019A2 (pt) 2018-01-30
US20230279007A1 (en) 2023-09-07
EP3244891B9 (en) 2022-11-16
AU2016206589B2 (en) 2020-09-10
US11702417B2 (en) 2023-07-18
PL3244891T3 (pl) 2022-12-27
DK3244891T3 (da) 2022-10-24
IL270945A (en) 2020-01-30
ES2928714T3 (es) 2022-11-22
TW201636341A (zh) 2016-10-16

Similar Documents

Publication Publication Date Title
EA201791624A1 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
EA201991369A1 (ru) Модифицированные направляющие рнк
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX2022007933A (es) Compuestos de polimetino y su uso como etiquetas fluorescentes.
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
MX2021009672A (es) Regulacion transcripcional guiada por acido ribonucleico.
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201491953A1 (ru) СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
IN2015DN00438A (ru)
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
MX2015011386A (es) Metodo para tratar cancer pancreatico.
EA201691413A1 (ru) Селективные антагонисты nr2b
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
MY194135A (en) Treatment and diagnosis of inflammatory disorders
EA202190500A3 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК
EA201790642A1 (ru) Аллель-специфическая терапия для гаплотипов болезни хантингтона
IL267231A (en) Methods of treating diseases associated with ilc2 cells
IL262951A (en) Methods of drug therapy associated with ilc3 cells